xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT06003088</url>
    </required_header>
    <id_info>
      <org_study_id>HSK7653-105</org_study_id>
      <nct_id>NCT06003088</nct_id>
    </id_info>
    <brief_title>Relative Bioavailability and Pharmacodynamics of HSK7653 in Healthy Volunteers</brief_title>
    <official_title>A Randomized, Open-label, Two-Way Crossover Study to Evaluate Relative Bioavailability and Pharmacodynamics of Two Doses of HSK7653 in Healthy Volunteers</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Haisco Pharmaceutical Group Co., Ltd.</agency>
        <agency_class>Industry</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>Haisco Pharmaceutical Group Co., Ltd.</source>
    <oversight_info>
      <has_dmc>No</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        To investigate the relative bioavailability of HSK7653(5mg) given as formulation A versus&#xD;
        formulation B.&#xD;
  &#xD;
        To investigate the relative bioavailability of HSK7653(25mg) given as formulation A versus&#xD;
        formulation B.&#xD;
  &#xD;
        To investigate safety and pharmacodynamics of two doses of HSK7653 in healthy male subjects.&#xD;
      </textblock>
    </brief_summary>
    <overall_status>Completed</overall_status>
    <start_date type="Actual">June 15, 2022</start_date>
    <completion_date type="Actual">September 9, 2022</completion_date>
    <primary_completion_date type="Actual">August 12, 2022</primary_completion_date>
    <phase>Phase 1</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Randomized</allocation>
      <intervention_model>Crossover Assignment</intervention_model>
      <primary_purpose>Treatment</primary_purpose>
      <masking>None (Open Label)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>Relative bioavailability (F)</measure>
      <time_frame>Pre-dose，0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168 and 336 hours post-dose.</time_frame>
      <description>To Evaluate Relative Bioavailability (F) of Two Doses of HSK7653 in Healthy Volunteers.&#xD;
  Relative bioavailability of HSK7653(5mg) given as formulation A versus formulation B=AUC(0-t)(HSK7653(5mg) Formulation A)/AUC(0-t)(HSK7653(5mg) Formulation B).&#xD;
  Relative bioavailability of HSK7653(25mg) given as formulation A versus formulation B=AUC(0-t)(HSK7653(25mg) Formulation A)/AUC(0-t)(HSK7653(25mg) Formulation B).</description>
    </primary_outcome>
    <primary_outcome>
      <measure>AUC(0-t)</measure>
      <time_frame>Pre-dose，0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168 and 336 hours post-dose.</time_frame>
      <description>The pharmacokinetic parameters of HSK7653 in plasma</description>
    </primary_outcome>
    <primary_outcome>
      <measure>AUC(0-∞)</measure>
      <time_frame>Pre-dose，0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168 and 336 hours post-dose.</time_frame>
      <description>The pharmacokinetic parameters of HSK7653 in plasma</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Cmax</measure>
      <time_frame>Pre-dose，0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168 and 336 hours post-dose.</time_frame>
      <description>The pharmacokinetic parameters of HSK7653 in plasma</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Tmax</measure>
      <time_frame>Pre-dose，0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168 and 336 hours post-dose.</time_frame>
      <description>The pharmacokinetic parameters of HSK7653 in plasma</description>
    </primary_outcome>
    <primary_outcome>
      <measure>t1/2</measure>
      <time_frame>Pre-dose，0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168 and 336 hours post-dose.</time_frame>
      <description>The pharmacokinetic parameters of HSK7653 in plasma</description>
    </primary_outcome>
    <primary_outcome>
      <measure>λz</measure>
      <time_frame>Pre-dose，0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168 and 336 hours post-dose.</time_frame>
      <description>The pharmacokinetic parameters of HSK7653 in plasma</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Vd/F</measure>
      <time_frame>Pre-dose，0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168 and 336 hours post-dose.</time_frame>
      <description>The pharmacokinetic parameters of HSK7653 in plasma</description>
    </primary_outcome>
    <primary_outcome>
      <measure>CL/F</measure>
      <time_frame>Pre-dose，0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168 and 336 hours post-dose.</time_frame>
      <description>The pharmacokinetic parameters of HSK7653 in plasma</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>The Safety of HSK7653</measure>
      <time_frame>From First dose until Follow up visit, assessed up to 3 months.</time_frame>
      <description>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>AUEC(0-last)</measure>
      <time_frame>Pre-dose，0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168 and 336 hours post-dose.</time_frame>
      <description>The pharmacodynamic parameters of HSK7653 in plasma</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>ECmax</measure>
      <time_frame>Pre-dose，0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168 and 336 hours post-dose.</time_frame>
      <description>The pharmacodynamic parameters of HSK7653 in plasma</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>ETmax</measure>
      <time_frame>Pre-dose，0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168 and 336 hours post-dose.</time_frame>
      <description>The pharmacodynamic parameters of HSK7653 in plasma</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>DPP-4(WAI-2W)</measure>
      <time_frame>Pre-dose，0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168 and 336 hours post-dose.</time_frame>
      <description>The pharmacodynamic parameters of HSK7653 in plasma</description>
    </secondary_outcome>
    <number_of_arms>4</number_of_arms>
    <enrollment type="Actual">48</enrollment>
    <condition>Healthy</condition>
    <arm_group>
      <arm_group_label>HSK7653(5mg) Sequence A(Formulation A + Formulation B)</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Participants will receive a single oral dose of treatment 1: Formulation A followed by a washout period of at least 36 days from first dose of HSK7653(5mg). After the washout period, participants will receive a single oral dose of Treatment 2: HSK7653(5mg) Formulation B.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>HSK7653(5mg) Sequence B(Formulation B + Formulation A)</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Participants will receive a single oral dose of treatment 1: Formulation B followed by a washout period of at least 36 days from first dose of HSK7653(5mg). After the washout period, participants will receive a single oral dose of Treatment 2: HSK7653(5mg) Formulation A.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>HSK7653(25mg) Sequence A(Formulation A + Formulation B)</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Participants will receive a single oral dose of treatment 1: Formulation A followed by a washout period of at least 36 days from first dose of HSK7653(25mg). After the washout period, participants will receive a single oral dose of Treatment 2: HSK7653(25mg) Formulation B.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>HSK7653(25mg) Sequence B(Formulation B + Formulation A)</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Participants will receive a single oral dose of treatment 1: Formulation B followed by a washout period of at least 36 days from first dose of HSK7653(25mg). After the washout period, participants will receive a single oral dose of Treatment 2: HSK7653(25mg) Formulation A.</description>
    </arm_group>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>HSK7653(5mg)</intervention_name>
      <description>Participants will receive a single oral dose of HSK7653(5mg) Formulation A Or a single oral dose of HSK7653(5mg) Formulation B on Day 1 Period 1. Depending on what Formulation was received on Day 1 Period 1, participants will receive either a single oral dose of HSK7653(5mg) Formulation A Or a single oral dose of HSK7653(5mg) Formulation B on Day 1 of Period 2. Each period lasts for 15 days.</description>
      <arm_group_label>HSK7653(5mg) Sequence A(Formulation A + Formulation B)</arm_group_label>
      <arm_group_label>HSK7653(5mg) Sequence B(Formulation B + Formulation A)</arm_group_label>
      <other_name>HSK7653</other_name>
    </intervention>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>HSK7653(25mg)</intervention_name>
      <description>Participants will receive a single oral dose of HSK7653(25mg) Formulation A Or a single oral dose of HSK7653(25mg) Formulation B on Day 1 Period 1. Depending on what Formulation was received on Day 1 Period 1, participants will receive either a single oral dose of HSK7653(25mg) Formulation A Or a single oral dose of HSK7653(25mg) Formulation B on Day 1 of Period 2. Each period lasts for 15 days.</description>
      <arm_group_label>HSK7653(25mg) Sequence A(Formulation A + Formulation B)</arm_group_label>
      <arm_group_label>HSK7653(25mg) Sequence B(Formulation B + Formulation A)</arm_group_label>
      <other_name>HSK7653</other_name>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            1. Healthy male and female subjects, age ≥18 years old，with appropriate sex ratio；&#xD;
  &#xD;
            2. A total body weight ≥40 kg for females and ≥50 kg for males；BMI of 19 to 26&#xD;
               kg/m^2(inclusive);&#xD;
  &#xD;
            3. Subjects(and their partners) volunteered to use effective physical contraception, had&#xD;
               no plans to have children or donate sperm/eggs from 14 days before the first dose to 6&#xD;
               months after the last dose;&#xD;
  &#xD;
            4. Evidence of a personally signed and dated informed consent document indicating that&#xD;
               the subject has been informed of all pertinent aspects of the study.&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            1. Subjects who are allergic to two or more medicine, foods or pollens or have a history&#xD;
               of allergy to the investigational product and the related compounds;&#xD;
  &#xD;
            2. Have a history of severe unconscious hypoglycemia；&#xD;
  &#xD;
            3. Clinical evidence or history of any of the following diseases:&#xD;
  &#xD;
                 -  Inflammatory bowel disease, gastritis, ulcers, bile duct stones, or&#xD;
                    gastrointestinal bleeding&#xD;
  &#xD;
                 -  Major gastrointestinal surgery (e.g., gastrectomy, gastrostomy, or enterectomy)&#xD;
  &#xD;
                 -  Pancreatic injury or pancreatitis&#xD;
  &#xD;
                 -  Abnormal liver function tests (such as ALT, AST, serum bilirubin) , indicating&#xD;
                    liver disease or liver injury&#xD;
  &#xD;
                 -  Renal insufficiency&#xD;
  &#xD;
                 -  Urinary tract obstruction or difficulty in bladder emptying;&#xD;
  &#xD;
            4. Evidence or history of chronic or serious diseases of the blood system, circulatory&#xD;
               system, digestive system, urinary system, respiratory system, nervous system, immune&#xD;
               system, endocrine system, mental disorders, metabolic disorders, or any other diseases&#xD;
               that may affect the results of the study;&#xD;
  &#xD;
            5. Serious trauma and surgery within 3 month prior to Screening;&#xD;
  &#xD;
            6. Use of vaccines within 1 month prior to dosing;&#xD;
  &#xD;
            7. Use of prescription within 1 month prior to dosing，or use of nonprescription&#xD;
               drugs（i.e. vitamins and herbal medicines）within 14 days prior to dosing;&#xD;
  &#xD;
            8. Participation in another trial with an investigational drug or instrument within 3&#xD;
               months prior to dosing and for the duration of the study;&#xD;
  &#xD;
            9. History of regular alcohol consumption exceeding 14 drinks/week (1 drink = 150 mL of&#xD;
               wine or 360 mL of beer or 45 mL of hard liquor) within 6 months of Screening.&#xD;
  &#xD;
           10. Use of alcohol during the trial,or have a positive result for alcohol breath test;&#xD;
  &#xD;
           11. Smoking ≥5 cigarettes per day within 3 months prior to Screening;&#xD;
  &#xD;
           12. Blood donation or loss of blood for≥ 400 mL or received blood transfusion or use of&#xD;
               blood products within 3 months prior to Screening, or blood donation program for the&#xD;
               duration of the study and for 1 month after the trial；&#xD;
  &#xD;
           13. Drinking excessive amounts of tea, coffee, and/or caffeinated beverages daily (average&#xD;
               more than 8 cups per day,1 cup =250 mL) within 3 months prior to Screening;&#xD;
  &#xD;
           14. Use of grapefruit, pomelo, dragon fruit, mango and other fruits or related products&#xD;
               that may affect metabolic enzymes within 7 days prior to dosing;&#xD;
  &#xD;
           15. Use of products containing alcohol within 48 hours prior to dosing and for the&#xD;
               duration of the study;&#xD;
  &#xD;
           16. Smoking or using any tobacco product within 48 hours prior to dosing and for the&#xD;
               duration of the study;&#xD;
  &#xD;
           17. Strenuous activities within 48 hours prior to dosing;&#xD;
  &#xD;
           18. Use of chocolate, food or beverages containing caffeine or xanthine within 48 hours&#xD;
               prior to dosing;&#xD;
  &#xD;
           19. History of drug abuse or drug dependence;&#xD;
  &#xD;
           20. Human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg),&#xD;
               hepatitis C virus (HCV) antibody, or Treponema pallidum antibody (TPPA) has a positive&#xD;
               result;&#xD;
  &#xD;
           21. Any clinically significant physical examination, vital signs, electrocardiogram or&#xD;
               clinical laboratory measurement abnormalities during screening, or Screening 12-lead&#xD;
               ECG demonstrating QT interval &gt;440 msec for males and &gt;420 msec for females,or FPG&lt;&#xD;
               3.9mmol/L or &gt; 6.1mmol/L;&#xD;
  &#xD;
           22. Pregnant or lactating women, or female subjects whose pregnancy test results are&#xD;
               positive;&#xD;
  &#xD;
           23. Lactose intolerant；&#xD;
  &#xD;
           24. Subjects who have a history of fainting needles and blood, or who cannot tolerate&#xD;
               venipuncture blood sampling;&#xD;
  &#xD;
           25. Difficulty in swallowing tablets and capsules;&#xD;
  &#xD;
           26. Special dietary requirements (e.g. vegetarians) or cannot follow a uniform diet during&#xD;
               the trial;&#xD;
  &#xD;
           27. Unable to cooperate to complete the study due to other reasons, or in the judgment of&#xD;
               the investigator, would make the subject inappropriate for entry into this study.&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>N/A</maximum_age>
      <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
    </eligibility>
    <location>
      <facility>
        <name>The First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine</name>
        <address>
          <city>Shenyang</city>
          <state>Liaoning</state>
          <country>China</country>
        </address>
      </facility>
    </location>
    <location_countries>
      <country>China</country>
    </location_countries>
    <verification_date>August 2023</verification_date>
    <study_first_submitted>January 11, 2023</study_first_submitted>
    <study_first_submitted_qc>August 18, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 21, 2023</study_first_posted>
    <last_update_submitted>August 22, 2023</last_update_submitted>
    <last_update_submitted_qc>August 22, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 24, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT06003088
  org study id: HSK7653-105
  nct id: NCT06003088
  lead sponsor: 
  has dmc: No
  is fda regulated drug: No
  is fda regulated device: No
  To investigate the relative bioavailability of HSK7653(5mg) given as formulation A versus
        formulation B.
  
        To investigate the relative bioavailability of HSK7653(25mg) given as formulation A versus
        formulation B.
  
        To investigate safety and pharmacodynamics of two doses of HSK7653 in healthy male subjects.
  allocation: Randomized
  intervention model: Crossover Assignment
  primary purpose: Treatment
  masking: None (Open Label)
  measure: Relative bioavailability (F)
  time frame: Pre-dose，0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168 and 336 hours post-dose.
  description: To Evaluate Relative Bioavailability (F) of Two Doses of HSK7653 in Healthy Volunteers.
  Relative bioavailability of HSK7653(5mg) given as formulation A versus formulation B=AUC(0-t)(HSK7653(5mg) Formulation A)/AUC(0-t)(HSK7653(5mg) Formulation B).
  Relative bioavailability of HSK7653(25mg) given as formulation A versus formulation B=AUC(0-t)(HSK7653(25mg) Formulation A)/AUC(0-t)(HSK7653(25mg) Formulation B).
  measure: AUC(0-t)
  time frame: Pre-dose，0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168 and 336 hours post-dose.
  description: The pharmacokinetic parameters of HSK7653 in plasma
  measure: AUC(0-∞)
  time frame: Pre-dose，0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168 and 336 hours post-dose.
  description: The pharmacokinetic parameters of HSK7653 in plasma
  measure: Cmax
  time frame: Pre-dose，0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168 and 336 hours post-dose.
  description: The pharmacokinetic parameters of HSK7653 in plasma
  measure: Tmax
  time frame: Pre-dose，0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168 and 336 hours post-dose.
  description: The pharmacokinetic parameters of HSK7653 in plasma
  measure: t1/2
  time frame: Pre-dose，0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168 and 336 hours post-dose.
  description: The pharmacokinetic parameters of HSK7653 in plasma
  measure: λz
  time frame: Pre-dose，0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168 and 336 hours post-dose.
  description: The pharmacokinetic parameters of HSK7653 in plasma
  measure: Vd/F
  time frame: Pre-dose，0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168 and 336 hours post-dose.
  description: The pharmacokinetic parameters of HSK7653 in plasma
  measure: CL/F
  time frame: Pre-dose，0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168 and 336 hours post-dose.
  description: The pharmacokinetic parameters of HSK7653 in plasma
  measure: The Safety of HSK7653
  time frame: From First dose until Follow up visit, assessed up to 3 months.
  description: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.
  measure: AUEC(0-last)
  time frame: Pre-dose，0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168 and 336 hours post-dose.
  description: The pharmacodynamic parameters of HSK7653 in plasma
  measure: ECmax
  time frame: Pre-dose，0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168 and 336 hours post-dose.
  description: The pharmacodynamic parameters of HSK7653 in plasma
  measure: ETmax
  time frame: Pre-dose，0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168 and 336 hours post-dose.
  description: The pharmacodynamic parameters of HSK7653 in plasma
  measure: DPP-4(WAI-2W)
  time frame: Pre-dose，0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168 and 336 hours post-dose.
  description: The pharmacodynamic parameters of HSK7653 in plasma
  arm group label: HSK7653(5mg) Sequence A(Formulation A + Formulation B)
  arm group type: Experimental
  description: Participants will receive a single oral dose of treatment 1: Formulation A followed by a washout period of at least 36 days from first dose of HSK7653(5mg). After the washout period, participants will receive a single oral dose of Treatment 2: HSK7653(5mg) Formulation B.
  arm group label: HSK7653(5mg) Sequence B(Formulation B + Formulation A)
  arm group type: Experimental
  description: Participants will receive a single oral dose of treatment 1: Formulation B followed by a washout period of at least 36 days from first dose of HSK7653(5mg). After the washout period, participants will receive a single oral dose of Treatment 2: HSK7653(5mg) Formulation A.
  arm group label: HSK7653(25mg) Sequence A(Formulation A + Formulation B)
  arm group type: Experimental
  description: Participants will receive a single oral dose of treatment 1: Formulation A followed by a washout period of at least 36 days from first dose of HSK7653(25mg). After the washout period, participants will receive a single oral dose of Treatment 2: HSK7653(25mg) Formulation B.
  arm group label: HSK7653(25mg) Sequence B(Formulation B + Formulation A)
  arm group type: Experimental
  description: Participants will receive a single oral dose of treatment 1: Formulation B followed by a washout period of at least 36 days from first dose of HSK7653(25mg). After the washout period, participants will receive a single oral dose of Treatment 2: HSK7653(25mg) Formulation A.
  intervention type: Drug
  intervention name: HSK7653(5mg)
  description: Participants will receive a single oral dose of HSK7653(5mg) Formulation A Or a single oral dose of HSK7653(5mg) Formulation B on Day 1 Period 1. Depending on what Formulation was received on Day 1 Period 1, participants will receive either a single oral dose of HSK7653(5mg) Formulation A Or a single oral dose of HSK7653(5mg) Formulation B on Day 1 of Period 2. Each period lasts for 15 days.
  arm group label: HSK7653(5mg) Sequence A(Formulation A + Formulation B)
  arm group label: HSK7653(5mg) Sequence B(Formulation B + Formulation A)
  other name: HSK7653
  intervention type: Drug
  intervention name: HSK7653(25mg)
  description: Participants will receive a single oral dose of HSK7653(25mg) Formulation A Or a single oral dose of HSK7653(25mg) Formulation B on Day 1 Period 1. Depending on what Formulation was received on Day 1 Period 1, participants will receive either a single oral dose of HSK7653(25mg) Formulation A Or a single oral dose of HSK7653(25mg) Formulation B on Day 1 of Period 2. Each period lasts for 15 days.
  arm group label: HSK7653(25mg) Sequence A(Formulation A + Formulation B)
  arm group label: HSK7653(25mg) Sequence B(Formulation B + Formulation A)
  other name: HSK7653
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: N/A
  healthy volunteers: Accepts Healthy Volunteers
  facility: 
  country: China
  responsible party type: Sponsor